Risk Factors for Cholangiocarcinoma

Overview

Journal Hepatology

Specialty Gastroenterology

Date 2011 Apr 14

PMID 21488076

Citations 412

Authors

Gia L Tyson

Hashem B El-Serag

Affiliations

Soon will be listed here.

Abstract

Cholangiocarcinoma (CC) is the second most common primary hepatic malignancy after hepatocellular cancer. CC accounts for approximately 10%-25% of all hepatobiliary malignancies. There are considerable geographic and demographic variations in the incidence of CC. There are several established risk factors for CC, including parasitic infections, primary sclerosing cholangitis, biliary-duct cysts, hepatolithiasis, and toxins. Other less-established potential risk factors include inflammatory bowel disease, hepatitis C virus, hepatitis B virus, cirrhosis, diabetes, obesity, alcohol drinking, tobacco smoking, and host genetic polymorphisms. In studies where the distinction between intra- and extrahepatic CC was used, some potential risk factors seem to have a differential effect on CC, depending on the site. Therefore, the consistent use of a more refined classification would allow a better understanding of risk factors for CC.

Citing Articles

Evaluation of an Mutation FastTrack Assay for Patients with Cholangiocarcinoma.

Winter M, Ebner S, Scheuber N, Schulze F, Kinzler M, Walter D Cancers (Basel). 2025; 17(5).

PMID: 40075667 PMC: 11898960. DOI: 10.3390/cancers17050820.

Research trends and hotspots evolution of artificial intelligence for cholangiocarcinoma over the past 10 years: a bibliometric analysis.

Wang K, Li Y, Yang S, Li F Front Oncol. 2025; 14:1454411.

PMID: 40017633 PMC: 11865243. DOI: 10.3389/fonc.2024.1454411.

Management of intrahepatic cholangiocarcinoma: a review for clinicians.

Colangelo M, Di Martino M, Polidoro M, Forti L, Tober N, Gennari A Gastroenterol Rep (Oxf). 2025; 13:goaf005.

PMID: 39867595 PMC: 11769681. DOI: 10.1093/gastro/goaf005.

Exploring the effects of gut microbiota on cholangiocarcinoma progression by patient-derived organoids.

Lederer A, Gorrissen N, Nguyen T, Kreutz C, Rasel H, Bartsch F J Transl Med. 2025; 23(1):34.

PMID: 39789543 PMC: 11716211. DOI: 10.1186/s12967-024-06012-x.

Temporal trends and patterns for early- and late-onset adult liver cancer incidence vary by race/ethnicity, subsite, and histologic type in the United States from 2000 to 2019.

Hsieh M, Ratnapradipa K, Rozek L, Wen S, Chiu Y, Peters E Cancer Causes Control. 2025; .

PMID: 39786651 DOI: 10.1007/s10552-024-01955-4.

References

Gatto M, Bragazzi M, Semeraro R, Napoli C, Gentile R, Torrice A . Cholangiocarcinoma: update and future perspectives. Dig Liver Dis. 2010; 42(4):253-60. DOI: 10.1016/j.dld.2009.12.008. View

Kornfeld D, Ekbom A, Ihre T . Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study. Scand J Gastroenterol. 1997; 32(10):1042-5. DOI: 10.3109/00365529709011222. View

Bergquist A, Glaumann H, Persson B, Broome U . Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology. 1998; 27(2):311-6. DOI: 10.1002/hep.510270201. View

Sripa B, Pairojkul C . Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol. 2008; 24(3):349-56. PMC: 4130346. DOI: 10.1097/MOG.0b013e3282fbf9b3. View

Lindkvist B, Benito de Valle M, Gullberg B, Bjornsson E . Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology. 2010; 52(2):571-7. DOI: 10.1002/hep.23678. View

Welzel T, Graubard B, El-Serag H, Shaib Y, Hsing A, Davila J . Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007; 5(10):1221-8. PMC: 2083573. DOI: 10.1016/j.cgh.2007.05.020. View

Blechacz B, Gores G . Cholangiocarcinoma. Clin Liver Dis. 2008; 12(1):131-50, ix. DOI: 10.1016/j.cld.2007.11.003. View

Watanabe Y, Toki A, Todani T . Bile duct cancer developed after cyst excision for choledochal cyst. J Hepatobiliary Pancreat Surg. 1999; 6(3):207-12. DOI: 10.1007/s005340050108. View

Yamaguchi M . Congenital choledochal cyst. Analysis of 1,433 patients in the Japanese literature. Am J Surg. 1980; 140(5):653-7. DOI: 10.1016/0002-9610(80)90051-3. View

10.

Voyles C, Smadja C, SHANDS W, Blumgart L . Carcinoma in choledochal cysts. Age-related incidence. Arch Surg. 1983; 118(8):986-8. DOI: 10.1001/archsurg.1983.01390080088022. View

11.

Lipshutz G, Brennan T, Warren R . Thorotrast-induced liver neoplasia: a collective review. J Am Coll Surg. 2002; 195(5):713-8. DOI: 10.1016/s1072-7515(02)01287-5. View

12.

Zhou Y, Yin Z, Yang J, Li B, Shao W, Xu F . Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol. 2008; 14(4):632-5. PMC: 2681159. DOI: 10.3748/wjg.14.632. View

13.

Kaewpitoon N, Kaewpitoon S, Pengsaa P, Sripa B . Opisthorchis viverrini: the carcinogenic human liver fluke. World J Gastroenterol. 2008; 14(5):666-74. PMC: 2683991. DOI: 10.3748/wjg.14.666. View

14.

Edil B, Cameron J, Reddy S, Lum Y, Lipsett P, Nathan H . Choledochal cyst disease in children and adults: a 30-year single-institution experience. J Am Coll Surg. 2008; 206(5):1000-5. DOI: 10.1016/j.jamcollsurg.2007.12.045. View

15.

Patel T . Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002; 2:10. PMC: 113759. DOI: 10.1186/1471-2407-2-10. View

16.

Patel T . Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001; 33(6):1353-7. DOI: 10.1053/jhep.2001.25087. View

17.

Kato I, KIDO C . Increased risk of death in thorotrast-exposed patients during the late follow-up period. Jpn J Cancer Res. 1987; 78(11):1187-92. View

18.

Welzel T, Mellemkjaer L, Gloria G, Sakoda L, Hsing A, El Ghormli L . Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer. 2006; 120(3):638-41. DOI: 10.1002/ijc.22283. View

19.

Shaib Y, El-Serag H, Davila J, Morgan R, McGlynn K . Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology. 2005; 128(3):620-6. DOI: 10.1053/j.gastro.2004.12.048. View

20.

Hoblinger A, Grunhage F, Sauerbruch T, Lammert F . Association of the c.3972C>T variant of the multidrug resistance-associated protein 2 Gene (MRP2/ABCC2) with susceptibility to bile duct cancer. Digestion. 2009; 80(1):36-9. DOI: 10.1159/000212990. View